Clinical trial
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating…
NCT00053131 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00053131 |
|---|---|
| Title | Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia |
| Official title | High Dose Cytarabine And Mitoxantrone Therapy For Relapsed And Refractory Acute Myeloid And Lymphocytic Leukemia: Effects Of GM-CSF Versus G-CSF On Dendritic Cells And Leukemia Associated Antigen-Specific T-Lymphocytes |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | filgrastim, sargramostim, cytarabine, mitoxantrone hydrochloride |
| Start date | Jan 1, 1999 |
| Primary completion | Feb 1, 2004 |
| Completion | Feb 1, 2004 |
| First posted | Jan 28, 2003 |
| Last update posted | Mar 8, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: